Drug Trial Radar · NCT04608110
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
59
Planned (sponsor's estimate)
Start
Oct 30, 2020
Primary completion
Dec 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
\[Tolerability Assessment Part\] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2. \[Expansion Assessment Part\] The purpose is to compare the total AUC for AZA after administration of ASTX030 with that after administration of AZA injection at 75 mg/m2.
Conditions
- Myelodysplastic Syndrome (MDS)
Interventions
ASTX030 (AZA + CED)Drug
In Cycle 1 (28 days per cycle), subcutaneous (SC) AZA will be administered on Day 1, followed by oral AZA formulations and CED tablets on Days 2-7. In Cycle 2 and onward, oral AZA formulations and CED tablets will be administered on Day 1-7.
ASTX030 (AZA + CED)Drug
In Cycle 1 (28 days per cycle), ASTX030 will be administered on Days 1-7. In Cycle 2, SC AZA will be administered on Days 1-7 according to a crossover design. From Cycle 3 onward, ASTX030 will be administered on Days 1-7.
ASTX030 (AZA + CED)Drug
In Cycle 1 (28 days per cycle), SC AZA will be administered on Days 1-7. In Cycle 2, ASTX030 will be administered on Days 1-7 according to a crossover design. From Cycle 3 onward, ASTX030 will be administered on Days 1-7.
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Tolerability Assessment Part] AUC ratio of AZA after administration of oral AZA formulations in combination with CED tablets compared with SC administration of AZA injection.Time frame: Up to 1 month
- [Expansion Assessment Part] AUC ratio of AZA after administration of ASTX030 compared with SC administration of AZA injectionTime frame: Up to 2month
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Nippon Medical School Hospital
Bunkyō City, Japan · Recruiting
Fukushima Medical University Hospital
Fukushima, Japan · Recruiting
Saitama Medical University Hospital
Iruma, Japan · Recruiting
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan · Recruiting
Nagasaki University Hospital
Nagasaki, Japan · Recruiting
Osaka City General Hospital
Osaka, Japan · Recruiting
Kindai University Hospital
Sakai, Japan · Recruiting
NTT Medical Center Tokyo
Shinagawa-Ku, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku-Ku, Japan · Recruiting
Yamagata University Hospital
Yamagata, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.